Sonablate

Sonablate Corp., founded in 2004 and headquartered in Charlotte, North Carolina, is a pioneer and commercial leader in High-Intensity Focused Ultrasound (HIFU) for the focal treatment of prostate cancer and other prostate diseases. The company's Sonablate HIFU system offers a customizable, incision-free alternative to radical prostatectomy or radiation, aiming to preserve patient quality of life while providing effective disease control. With over 30,000 patients treated worldwide and FDA clearance secured in 2015, Sonablate has established a significant global footprint. The company operates as a private commercial-stage entity, generating revenue from the sale of its medical device platform to urology clinics and hospitals.

High-Intensity Focused Ultrasound (HIFU) system for tissue ablation, featuring real-time ultrasound feedback, robotic accuracy for focal therapy, and proprietary safety monitors (Tissue Change Monitoring, Total Acoustic Power, Reflexivity Index).

Sonablate competes in the focal therapy for prostate cancer market against other HIFU devices (e.g., EDAP TMS's Focal One) and alternative ablation technologies like cryotherapy, laser interstitial thermal therapy, and irreversible electroporation. Its first-mover FDA clearance and emphasis on real-time monitoring and customization are key differentiators in this competitive and evolving space.